A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled Phase IIa study of HH-003 to evaluate the
antiviral activity and safety in nucleos(t)ide analogues-treated chronic hepatitis B subjects
with low-level viremia. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of
the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate
co-transporting polypeptide (NTCP), the cellular receptor for HBV.